Gelesis Holdings Number of Employees 2021-2022 | GLS

Gelesis Holdings number of employees from 2021 to 2022. Number of employees can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures, expressed on a per share basis
Gelesis Holdings Annual Number of Employees
2021 103
2020 2
2019
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.078B $0.011B
Gelesis is a consumer-centered biotherapeutics company advancing a novel category of treatments for weight management and gut related chronic diseases. Gelesis, formerly known as Capstar Special Purpose Acquisition Corp., is based in BOSTON.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $151.795B 9.21
GSK (GSK) United Kingdom $59.851B 7.19
Bio-Rad Laboratories (BIO.B) United States $12.433B 27.47
Biohaven Pharmaceutical Holding (BHVN) United States $10.831B 0.00
QIAGEN (QGEN) Netherlands $9.374B 15.70
Ginkgo Bioworks Holdings (DNA) United States $5.569B 0.00
Arcus Biosciences (RCUS) United States $1.888B 36.85
Myovant Sciences (MYOV) United Kingdom $1.723B 0.00
Emergent Biosolutions (EBS) United States $1.047B 6.07
ADC Therapeutics SA (ADCT) Switzerland $0.370B 0.00
Zymeworks (ZYME) Canada $0.356B 0.00
Enzo Biochem (ENZ) United States $0.109B 0.00
SQZ Biotechnologies (SQZ) United States $0.067B 0.00
Ambrx Biopharma (AMAM) United States $0.042B 0.00